Traconazole, a generic anti-fungal agent that costs relatively less, shows some evidence of efficacy in metastatic prostate cancer which would make it an attractive proposition given the high costs associated with cancer treatments such as arbiraterone, said Pan Pantziarka, member of the Repurposing Drugs in Oncology (ReDO) project that researched the potential of the drug.

The low cost of itraconazole could make it an attractive cancer treatment in low and middle income countries.But there are a few roadblocks that must be addressed before this anti-fungal medication can reach the anti-cancer market, the researchers noted."Our intention in collecting data on re-purposed drugs is to do more than merely bringing it to the attention of the medical community," study author Lydie Meheus from the Anticancer Fund, Belgium.

Latest News from Lifestyle News Desk